Related Experiment Video
Updated: Jul 1, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.0K
Speech-Based Digital Biomarkers for Alzheimer's Research
Simona Schäfer1, Janna Herrmann1, Sol Tovar1
1ki:elements GmbH, Saarbrücken, Germany.
Methods in Molecular Biology (Clifton, N.J.)
|March 1, 2024
Summary
Speech analysis offers a promising, low-burden method for Alzheimer's Disease (AD) research. This chapter details methods for collecting and processing speech data to create valuable speech-based digital biomarkers for AD clinical studies.
Area of Science:
- Neuroscience
- Digital Health
- Biomarker Research
Background:
- Digital biomarkers are increasingly vital in Alzheimer's Disease (AD) research.
- Speech data offers objective, remote assessment of AD symptoms and cognition with minimal patient burden.
- Challenges exist in collecting, preparing, and interpreting speech data for clinical research.
Purpose of the Study:
- To outline the necessary methods for creating effective speech collection scenarios.
- To enable the generation of valuable speech-based digital biomarkers for AD clinical research.
Main Methods:
- Utilizing a dedicated pipeline for speech collection.
- Implementing preprocessing steps and algorithms for data analysis.
- Focusing on precise qualification and quantification of AD pathology from speech.
Main Results:
- The described methods facilitate the extraction of meaningful insights from speech data.
- Potential for more objective and accurate patient assessment in real-world settings.
- Enables multimodal variance analysis for predicting individual disease progression.
Conclusions:
- Standardized speech collection and analysis methods are crucial for AD research.
- Speech-based digital biomarkers can significantly enhance the understanding and monitoring of Alzheimer's Disease.
- This approach supports remote data collection and personalized disease progression modeling.
Related Concept Videos
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188

